Crospon logo

Home
About Us
Product Brochures
EndoFLIP® Technology

Clinical Applications

- Upper GI Surgery

- Bariatric Surgery

- Upper GI Imaging

- Cardiology

- Therapeutic Endoscopy

- Colorectal Imaging

Distributors
Newsroom
Events
Awards
Contact Us



 

 

New paper shows that esophageal distensibilty predicts symptom response in patients with eosinophilic esophagitis

2nd September 2013

A new paper from Northwestern University has been published the results of a prospective trial which describes the use of EndoFLIP distensibility measurements as a biomarker for symptomatic relief from eosiniphilic esophagitis (EoE).  This group’s pioneering work to date has highlighted that the current gold standard for the diagnosis of EoE, namely eosinophil count, has poor correlation with symptomatic resolution. The paper, Esophageal distensibility as a measure of disease severity in patients with eosinophilic esophagitis by Nicodème F, Hirano I, Chen J, Robinson K, Lin Z, Xiao Y, Gonsalves N, Kwasny MJ, Kahrilas PJ, Pandolfino JE. in Clin Gastroenterol Hepatol. 2013 Sep;11(9):1101-1107, concludes that reduced esopahgeal distensibility predicts risk for food impaction and the requirement for esophageal dilation in patients with eosiniphilic esophagitis. Furthermore it is concluded that the severity of mucosal eosinophilia was not predictive of outcome and had poor correlation with esophageal distensibility.

 

 
Newsroom Links
News Headlines
Upcoming Events
         
EndoFLIP logo   Crospon (USA) 701 Palomar Airport Rd, Carlsbad, CA 92011, USA. Phone: 1-855-CROSPON
Crospon (EU) Galway Business Park, Dangan, Galway, H91 P2DK, Ireland. Phone +353-91-519880